Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $81
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Equal-Weight rating on Gilead Sciences (NASDAQ:GILD) but lowered the price target from $84 to $81.
July 11, 2023 | 10:25 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Gilead Sciences but lowered the price target from $84 to $81.
The lowering of the price target by Barclays indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Gilead Sciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100